General Information of Drug (ID: DMU79X2)

Drug Name
YM-758 Drug Info
Synonyms
YM 758 Phosphate; (R)-(-)-N-[2-[3-[(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)carbonyl]piperidino]ethyl]-4-fluorobenzamide monophosphate; YM 758; N-[2-[(3R)-3-[(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)carbonyl]-1-piperidinyl]ethyl]-4-fluorobenzamide Phosphate
Indication
Disease Entry ICD 11 Status REF
Angina pectoris BA40 Phase 2 [1]
Cross-matching ID
PubChem CID
9894205
CAS Number
CAS 312752-85-5
TTD Drug ID
DMU79X2
VARIDT Drug ID
DR01466

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTP
Drug Status:
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [3]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [2]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [4]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [5]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [4]
Pravastatin DM6A0X7 Adult acute monocytic leukemia Approved [6]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [7]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [8]
Cerivastatin DMXCM7H Hyperlipidaemia 5C80 Approved [9]
PITAVASTATIN CALCIUM DM1UJO0 Dyslipidemia 5C80-5C81 Approved [6]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024920)
2 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
3 Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
4 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
5 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
6 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
7 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
8 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
9 FDA Drug Development and Drug Interactions